Drug Profile
Research programme: tuberculosis therapeutics - Lilly TB Drug Discovery Initiative
Alternative Names: BIKAKEN; CPZEN-45Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Institute of Microbial Chemistry; Microbial Chemistry Research Foundation; Summit plc
- Developer Eli Lilly and Company
- Class Nucleosides; Small molecules
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Tuberculosis in USA (Inhalation)
- 24 Aug 2017 Infectious Disease Research Institute and Zhejiang Hisun Pharmaceutical agree to co-develop CPZEN 45 for tuberculosis
- 20 Feb 2015 Summit Corporation is now called Summit Therapeuitcs